146 related articles for article (PubMed ID: 18193422)
21. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
22. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
23. Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial.
Donskov F; Hokland M; Marcussen N; Torp Madsen HH; von der Maase H
Br J Cancer; 2006 Jan; 94(2):218-26. PubMed ID: 16434984
[TBL] [Abstract][Full Text] [Related]
24. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
25. G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte.
Sconocchia G; Fujiwara H; Rezvani K; Keyvanfar K; El Ouriaghli F; Grube M; Melenhorst J; Hensel N; Barrett AJ
J Leukoc Biol; 2004 Dec; 76(6):1214-9. PubMed ID: 15345723
[TBL] [Abstract][Full Text] [Related]
26. Enhancement by stem cell factor of interleukin-2 (IL-2)-induced DNA synthesis in human decidual CD16- CD56bright natural killer cells mediated by increased expression of the IL-2 receptor alpha chain.
Umekage H; Saito S; Morikawa H
J Reprod Immunol; 1998 Oct; 40(1):1-24. PubMed ID: 9862254
[TBL] [Abstract][Full Text] [Related]
27. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
28. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.
Suttmann H; Jacobsen M; Reiss K; Jocham D; Böhle A; Brandau S
J Urol; 2004 Oct; 172(4 Pt 1):1490-5. PubMed ID: 15371877
[TBL] [Abstract][Full Text] [Related]
30. Interleukin 4 (IL-4) blocks the IL-2-induced increased in natural killer activity and DNA synthesis of decidual CD16-CD56bright NK cells by inhibiting expression of the IL-2 receptor alpha, beta, and gamma.
Saito S; Umekage H; Nishikawa K; Morii T; Narita N; Enomoto M; Sakakura S; Harada N; Ichijo M; Morikawa H
Cell Immunol; 1996 May; 170(1):71-7. PubMed ID: 8660801
[TBL] [Abstract][Full Text] [Related]
31. Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.
Kondadasula SV; Roda JM; Parihar R; Yu J; Lehman A; Caligiuri MA; Tridandapani S; Burry RW; Carson WE
Blood; 2008 Apr; 111(8):4173-83. PubMed ID: 18174382
[TBL] [Abstract][Full Text] [Related]
32. In vivo activation of LAK cells during systemic IL-2 therapy.
Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
[No Abstract] [Full Text] [Related]
33. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.
Brehm C; Huenecke S; Quaiser A; Esser R; Bremm M; Kloess S; Soerensen J; Kreyenberg H; Seidl C; Becker PS; Mühl H; Klingebiel T; Bader P; Passweg JR; Schwabe D; Koehl U
PLoS One; 2011; 6(11):e27351. PubMed ID: 22096557
[TBL] [Abstract][Full Text] [Related]
34. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
35. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
Meropol NJ; Barresi GM; Fehniger TA; Hitt J; Franklin M; Caligiuri MA
Cancer Immunol Immunother; 1998 Aug; 46(6):318-26. PubMed ID: 9756416
[TBL] [Abstract][Full Text] [Related]
37. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells.
Cooper MA; Fehniger TA; Ponnappan A; Mehta V; Wewers MD; Caligiuri MA
Eur J Immunol; 2001 Mar; 31(3):792-801. PubMed ID: 11241284
[TBL] [Abstract][Full Text] [Related]
39. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
Merad M; Angevin E; Wolfers J; Flament C; Lorenzi I; Triebel F; Escudier B; Zitvogel L
J Immunother; 2000; 23(3):369-78. PubMed ID: 10838666
[TBL] [Abstract][Full Text] [Related]
40. Activation of human NK cells by staphylococci and lactobacilli requires cell contact-dependent costimulation by autologous monocytes.
Haller D; Serrant P; Granato D; Schiffrin EJ; Blum S
Clin Diagn Lab Immunol; 2002 May; 9(3):649-57. PubMed ID: 11986274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
